A case report of cryptococcal meningitis associated with ruxolitinib.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
entrez:
30
3
2020
pubmed:
30
3
2020
medline:
14
4
2020
Statut:
ppublish
Résumé
We herein report a 76-year-old Japanese man with myelofibrosis who developed cryptococcal meningitis. After treatment for 5 months with ruxolitinib, the patient presented with fever and disturbance of consciousness. Marked nuchal stiffness was noted. The magnetic resonance imaging results of the brain were normal. Lumbar puncture showed an opening cerebrospinal fluid (CSF) pressure of 110 mm H2O, pleocytosis (85 mononuclear cells and 222 polymorphonuclear cells/μL), decreased CSF/serum glucose ratio (43%), and elevated protein (194 mg/dL). Blood and CSF cultures grew no bacteria or fungi. However, cryptococcal antigen was detected in the blood and CSF samples. We discontinued ruxolitinib and started administration of amphotericin B. His condition improved gradually 1 week after initiation of treatment. There have been only a few reports on cryptococcal meningitis associated with ruxolitinib. Physicians should consider the possibility of cryptococcal meningitis in patients receiving ruxolitinib.
Identifiants
pubmed: 32221077
doi: 10.1097/MD.0000000000019587
pii: 00005792-202003270-00018
pmc: PMC7220082
doi:
Substances chimiques
Nitriles
0
Pyrazoles
0
Pyrimidines
0
Amphotericin B
7XU7A7DROE
ruxolitinib
82S8X8XX8H
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e19587Références
BMJ Case Rep. 2014 Jun 02;2014:
pubmed: 24891492
Clin Cancer Res. 2013 Apr 15;19(8):1933-40
pubmed: 23406773
Ther Clin Risk Manag. 2012;8:95-103
pubmed: 22399854
J Immunol. 2012 Oct 15;189(8):4060-8
pubmed: 22984078
BMC Infect Dis. 2019 Mar 27;19(1):287
pubmed: 30917797
Ann Hematol. 2016 Jan;95(2):361-2
pubmed: 26486358
BMC Res Notes. 2012 Oct 05;5:552
pubmed: 23039051
Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i34-i42
pubmed: 30806708
Mycoses. 2018 Apr;61(4):245-255
pubmed: 29280197
Respir Med Case Rep. 2017 Jul 04;22:87-90
pubmed: 28721333
AIDS. 2009 Mar 27;23(6):701-6
pubmed: 19279443
Infect Dis (Lond). 2018 May;50(5):381-387
pubmed: 29251529
Blood. 2010 Apr 15;115(15):3109-17
pubmed: 20130243
Chest. 2013 May;143(5):1478-1479
pubmed: 23648912
PLoS Med. 2006 Jul;3(7):e270
pubmed: 16834459
Ann Hematol. 2014 Jun;93(6):1075-6
pubmed: 24173089
N Engl J Med. 2012 Mar 1;366(9):787-98
pubmed: 22375970
AIDS. 2010 Jan 28;24(3):405-10
pubmed: 19952714
Leukemia. 2016 Aug;30(8):1701-7
pubmed: 27211272
J Clin Oncol. 2011 Apr 1;29(10):1356-63
pubmed: 21300928
N Engl J Med. 2013 Jul 11;369(2):197-8
pubmed: 23841743
N Engl J Med. 2013 Aug 15;369(7):681-3
pubmed: 23944322
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
CA Cancer J Clin. 2009 May-Jun;59(3):171-91
pubmed: 19369682
Nat Rev Neurol. 2017 Jan;13(1):13-24
pubmed: 27886201
Cancer Res. 2015 Jun 1;75(11):2187-99
pubmed: 25832652
Clin Cancer Res. 2010 Apr 1;16(7):1988-96
pubmed: 20215535
Blood. 2013 Aug 15;122(7):1192-202
pubmed: 23770777
Haematologica. 2007 Dec;92(12):1585-9
pubmed: 18055979
Ther Clin Risk Manag. 2017 Feb 13;13:169-177
pubmed: 28243106
Eukaryot Cell. 2012 Feb;11(2):109-18
pubmed: 22140231
J Cell Sci. 2004 Mar 15;117(Pt 8):1281-3
pubmed: 15020666
J Immunol. 2007 Mar 1;178(5):2623-9
pubmed: 17312100
Br J Haematol. 2015 Jun;169(6):824-33
pubmed: 25824483